Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)
  4. Volume 24, Issue 14
  5. Article
Volume 24, Issue 14
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873

Abstract

Objective

COVID-19 is a potentially serious new infection first reported in North East Italy in Spring, 2020. Patients with adrenal insufficiency (AI) have a known increased risk of infections that could precipitate to adrenal crisis. Even COVID-19-related psycho-social impact could affect their health, requiring a dynamic adaptation of daily glucocorticoid (GC) therapy. The aim of this study was to evaluate the incidence of COVID-19 infection and self-reported outcomes in AI patients after the first pandemic waves.

Methods

It was an open-label, cross-sectional monocentric study on 84 (65 primary, 19 secondary) AI patients resident in Veneto and followed-up in our clinical Endocrine Unit. All patients underwent serological investigation of anti-SARS-CoV2 IgG, answered the purpose-built “ADDI-COVID” questionnaire in August, 2020, and were re-contacted to reevaluate COVID-19 infection occurrence in March-April, 2021.

Results

All patients resulted negative to the serological test for anti-SARS-CoV2 IgG at the end of the first pandemic wave. After the third wave, COVID-19 infection occurred in 8 patients without the need for hospitalization. Half patients felt an increased risk of COVID-19 infection, significantly associated with increased stress and GC stress dose. Only one patient reported stress-correlated adrenal crisis. The majority of AI workers changed working habits, significantly reducing COVID-19-related stress.

Conclusion

AI patients did not show an increased incidence of COVID-19, but the perception of increased COVID-19 infection risk significantly impacted their psychological well-being, working habits, and GC daily doses. Therapeutic patient education is crucial, especially for AI workers, to prevent and treat situations that could lead to an adrenal crisis.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/1871530322666220811103755
2024-04-26
2025-01-10

  • From This Site

    /content/journals/emiddt/10.2174/1871530322666220811103755
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BornsteinS.R. AllolioB. ArltW. BarthelA. Don-WauchopeA. HammerG.D. HusebyeE.S. MerkeD.P. MuradM.H. StratakisC.A. TorpyD.J. Diagnosis and treatment of primary adrenal insufficiency: An endocrine society clinical practice guideline.J. Clin. Endocrinol. Metab.2016101236438910.1210/jc.2015‑171026760044
     [Google Scholar]
  2. BetterleC. PresottoF. FurmaniakJ. Epidemiology, pathogenesis, and diagnosis of Addison’s disease in adults.J. Endocrinol. Invest.201942121407143310.1007/s40618‑019‑01079‑631321757
     [Google Scholar]
  3. CeccatoF. ScaroniC. Central adrenal insufficiency: Open issues regarding diagnosis and glucocorticoid treatment.Clin. Chem. Lab. Med.20195781125113510.1515/cclm‑2018‑082430427776
     [Google Scholar]
  4. AllolioB. Extensive expertise in endocrinology. Adrenal crisis.Eur. J. Endocrinol.20151723R115R12410.1530/EJE‑14‑082425288693
     [Google Scholar]
  5. HahnerS. SpinnlerC. FassnachtM. Burger-StrittS. LangK. MilovanovicD. BeuschleinF. WillenbergH.S. QuinklerM. AllolioB. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: A prospective study.J. Clin. Endocrinol. Metab.2015100240741610.1210/jc.2014‑319125419882
     [Google Scholar]
  6. ChabreO. GoichotB. ZenatyD. BertheratJ. Group 1. Epidemiology of primary and secondary adrenal insufficiency: Prevalence and incidence, acute adrenal insufficiency, long-term morbidity and mortality.Ann. Endocrinol. (Paris)201778649049410.1016/j.ando.2017.10.01029174931
     [Google Scholar]
  7. SabbadinC. BetterleC. ScaroniC. CeccatoF. Frequently asked questions in patients with adrenal insufficiency in the time of COVID-19.Front. Endocrinol. (Lausanne)20211280564710.3389/fendo.2021.80564735002978
     [Google Scholar]
  8. BancosI. HazeldineJ. ChortisV. HampsonP. TaylorA.E. LordJ.M. ArltW. Primary adrenal insufficiency is associated with impaired natural killer cell function: A potential link to increased mortality.Eur. J. Endocrinol.2017176447148010.1530/EJE‑16‑096928223394
     [Google Scholar]
  9. IsidoriA.M. VenneriM.A. GraziadioC. SimeoliC. FioreD. HasenmajerV. SbardellaE. GianfrilliD. PozzaC. PasqualettiP. MorroneS. SantoniA. NaroF. ColaoA. PivonelloR. LenziA. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): A single-blind, randomised controlled trial.Lancet Diabetes Endocrinol.20186317318510.1016/S2213‑8587(17)30398‑429229498
     [Google Scholar]
  10. SpiteriG. FieldingJ. DierckeM. CampeseC. EnoufV. GaymardA. BellaA. SognamiglioP. Sierra MorosM.J. RiutortA.N. DeminaY.V. MahieuR. BroasM. BengnérM. BudaS. SchillingJ. FilleulL. LepoutreA. SauraC. MaillesA. Levy-BruhlD. CoignardB. Bernard-StoecklinS. BehillilS. van der WerfS. ValetteM. LinaB. RiccardoF. NicastriE. CasasI. LarrauriA. Salom CastellM. PozoF. MaksyutovR.A. MartinC. Van RanstM. BossuytN. SiiraL. SaneJ. Tegmark-WisellK. PalmérusM. BrobergE.K. BeautéJ. JorgensenP. BundleN. PereyaslovD. AdlhochC. PukkilaJ. PebodyR. OlsenS. CiancioB.C. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020.Euro Surveill.2020259200017810.2807/1560‑7917.ES.2020.25.9.200017832156327
     [Google Scholar]
  11. CeccatoF. VoltanG. SabbadinC. CamozziV. Merante BoschinI. MianC. ZanottoV. DonatoD. BordignonG. CapizziA. CarrettaG. ScaroniC. Tele-medicine versus face-to-face consultation in endocrine outpatients clinic during COVID-19 outbreak: A single-center experience during the lockdown period.J. Endocrinol. Invest.20214481689169810.1007/s40618‑020‑01476‑233355915
     [Google Scholar]
  12. KienitzT. HahnerS. Burger-StrittS. QuinklerM. Therapeutic patient education for adrenal insufficiency under COVID-19 pandemic conditions.Exp. Clin. Endocrinol. Diabetes2021129324124910.1055/a‑1217‑720832767286
     [Google Scholar]
  13. ArltW. BaldewegS.E. PearceS.H.S. SimpsonH.L. Endocrinology in the time of COVID-19: Management of adrenal insufficiency.Eur. J. Endocrinol.20201831G25G3210.1530/EJE‑20‑036132379699
     [Google Scholar]
  14. IsidoriA.M. ArnaldiG. BoscaroM. FalorniA. GiordanoC. GiordanoR. PivonelloR. PofiR. HasenmajerV. VenneriM.A. SbardellaE. SimeoliC. ScaroniC. LenziA. COVID-19 infection and glucocorticoids: Update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency.J. Endocrinol. Invest.20204381141114710.1007/s40618‑020‑01266‑w32335855
     [Google Scholar]
  15. MartinoM. AboudN. ColaM.F. GiancolaG. CiarloniA. SalvioG. ArnaldiG. Impact of COVID-19 pandemic on psychophysical stress in patients with adrenal insufficiency: The CORTI-COVID study.J. Endocrinol. Invest.20214451075108410.1007/s40618‑020‑01422‑232946078
     [Google Scholar]
  16. CarosiG. MorelliV. Del SindacoG. SerbanA.L. CremaschiA. FrigerioS. RodariG. ProfkaE. IndirliR. MungariR. ResiV. OrsiE. FerranteE. DolciA. GiavoliC. ArosioM. MantovaniG. Adrenal insufficiency at the time of COVID-19: A retrospective study in patients referring to a tertiary center.J. Clin. Endocrinol. Metab.20211063e1354e136110.1210/clinem/dgaa793
     [Google Scholar]
  17. GrafA. MarcusH.J. BaldewegS.E. The direct and indirect impact of the COVID-19 pandemic on the care of patients with pituitary disease: A cross sectional study.Pituitary202124226226810.1007/s11102‑020‑01106‑333236181
     [Google Scholar]
  18. LiD. SureshM. AbbondanzaT. VaidyaA. BancosI. The impact of the COVID-19 pandemic on self-reported outcomes in patients with adrenal insufficiency.J. Clin. Endocrinol. Metab.20211067e2469e247910.1210/clinem/dgab33434042985
     [Google Scholar]
  19. Genis-MendozaA.D. Martínez-MagañaJ.J. López-NarváezM.L. González-CastroT.B. Juárez-RojopI.E. NicoliniH. Tovilla-ZárateC.A. Castillo-AvilaR.G. Mental health problems due to social isolation during the COVID-19 pandemic in a mexican population.Front. Public Health2021970345010.3389/fpubh.2021.70345034888275
     [Google Scholar]
  20. PilcherJ.J. DorseyL.L. GallowayS.M. EriksonD.N. Social isolation and sleep: Manifestation during COVID-19 quarantines.Front. Psychol.20221281076310.3389/fpsyg.2021.81076335082732
     [Google Scholar]
  21. PlebaniM. PadoanA. NegriniD. CarpinteriB. SciacovelliL. Diagnostic performances and thresholds: The key to harmonization in serological SARS-CoV-2 assays?Clin. Chim. Acta20205091710.1016/j.cca.2020.05.05032485157
     [Google Scholar]
  22. BetterleC. ZanchettaR. Update on autoimmune polyendocrine syndromes (APS).Acta Biomed.200374193312817789
     [Google Scholar]
  23. COVID-19 task force of the Department of Infectious Diseases and Information Technology Service, Istituto Superiore di Sanità. COVID-19 epidemic, National update.2021
     [Google Scholar]
  24. TresoldiA.S. SumiloD. PerrinsM. ToulisK.A. PreteA. ReddyN. WassJ.A.H. ArltW. NirantharakumarK. Increased infection risk in Addison’s disease and congenital adrenal hyperplasia.J. Clin. Endocrinol. Metab.2020105241842910.1210/clinem/dgz00631532828
     [Google Scholar]
  25. LandryM.L. Immunoglobulin M for acute infection: True or false?Clin. Vaccine Immunol.201623754054510.1128/CVI.00211‑1627193039
     [Google Scholar]
  26. GarelliS. Dalla CostaM. SabbadinC. BarolloS. RubinB. ScarpaR. MasieroS. FierabracciA. BizzarriC. CrinòA. CappaM. ValenziseM. MeloniA. De BellisA.M. GiordanoC. PresottoF. PerniolaR. CapalboD. SalernoM.C. StiglianoA. RadettiG. CamozziV. GreggioN.A. BogazziF. ChiodiniI. PagottoU. BlackS.K. ChenS. Rees SmithB. FurmaniakJ. WeberG. PigliaruF. De SanctisL. ScaroniC. BetterleC. Autoimmune polyendocrine syndrome type 1: An Italian survey on 158 patients.J. Endocrinol. Invest.202144112493251010.1007/s40618‑021‑01585‑634003463
     [Google Scholar]
  27. BastardP. OrlovaE. SozaevaL. LévyR. JamesA. SchmittM.M. OchoaS. KarevaM. RodinaY. GervaisA. Le VoyerT. RosainJ. PhilippotQ. NeehusA.L. ShawE. MigaudM. BizienL. EkwallO. BergS. BeccutiG. GhizzoniL. ThiriezG. PavotA. GoujardC. FrémondM.L. CarterE. RothenbuhlerA. LinglartA. MignotB. ComteA. CheikhN. HermineO. BreivikL. HusebyeE.S. HumbertS. RohrlichP. CoaquetteA. VuotoF. FaureK. MahlaouiN. KotnikP. BattelinoT. Trebušak PodkrajšekK. KisandK. FerréE.M.N. DiMaggioT. RosenL.B. BurbeloP.D. McIntyreM. KannN.Y. ShcherbinaA. PavlovaM. KolodkinaA. HollandS.M. ZhangS.Y. CrowY.J. NotarangeloL.D. SuH.C. AbelL. AndersonM.S. JouanguyE. NevenB. PuelA. CasanovaJ.L. LionakisM.S. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1.J. Exp. Med.20212187e2021055410.1084/jem.2021055433890986
     [Google Scholar]
  28. CarpinoA. BuganzaR. MatarazzoP. TuliG. PinonM. CalvoP.L. MontinD. LicciardiF. De SanctisL. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in two siblings: Same mutations but very different phenotypes.Genes (Basel)202112216910.3390/genes1202016933530632
     [Google Scholar]
  29. LiD. GenereN. BehnkenE. XhikolaM. AbbondanzaT. VaidyaA. BancosI. Determinants of self-reported health outcomes in adrenal insufficiency: A multisite survey study.J. Clin. Endocrinol. Metab.20211063e1408e141910.1210/clinem/dgaa66832995875
     [Google Scholar]
/content/journals/emiddt/10.2174/1871530322666220811103755
Loading
Serological Evidence and Self-reported Outcomes in Patients with Adrenal Insufficiency during the First Waves of COVID-19 in North-East Italy
Endocr Metab Immune Disord Drug Targets 24, 1677 (2024); https://doi.org/10.2174/1871530322666220811103755
/content/journals/emiddt/10.2174/1871530322666220811103755
/content/journals/emiddt/10.2174/1871530322666220811103755
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Adrenal insufficiency; cortisol response; COVID-19; glucocorticoid therapy; IgG anti-SARS-CoV-2; stress

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test